CDC's 2025 NIS-Teen data show HPV vaccine coverage flat for a fourth year, with rural adolescents 12 points behind urban peers in receiving ≥1 dose.
|Articles|June 1, 2004
Newborn respiratory problems: When the grunting and flaring won't go away
Respiratory signs and symptoms in newborns may reflect a problem that requires treatment or referral. A systems-based approach will help you recognize true respiratory distress and keep evaluation and management on track.
Advertisement
Advertisement
Related to this article
Semaglutide cut testosterone by half in early trial data — but one patient's rapid weight loss revealed a real risk. Our experts weigh the promise of GLP-1 therapy against how fast is too fast for teens.
Which labs actually change management? Our experts debate fasting insulin versus A1c, explain why total testosterone can mislead, and share the LH-to-FSH trick that helps settle ambiguous cases.
Most patients meet PMOS in a primary care office first. Our experts map the referral threshold and argue insulin resistance — not just androgens — should drive how aggressively PCPs treat.
Ovarian ultrasound doesn't apply to teens. Our experts walk through the 2-criteria threshold for adolescents, the "at risk" category, and why untreated menstrual irregularity carries real long-term consequences.
A global Lancet consensus just renamed PCOS to PMOS. Our experts explain why the shift moves care beyond the ovaries — and what it means for how clinicians talk to patients today.
Adolescent VALIANT subgroup data show pegcetacoplan cut proteinuria 75% vs placebo, supporting its expanded pediatric kidney indication.
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time AAV9 gene therapy, as the first treatment for pediatric MPS IIIA (Sanfilippo syndrome type A).
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Updated AAP guidance changes iron deficiency screening and treatment in children
2
FDA approves rebisufligene etisparvovec, first gene therapy for Sanfilippo syndrome type A
3
Pegcetacoplan reduces proteinuria, stabilizes kidney function in adolescents with C3G and IC-MPGN
4